PDL BioPharma Stock Hits New 52-Week Low (PDLI)

NEW YORK (TheStreet) -- PDL BioPharma (Nasdaq:PDLI) hit a new 52-week low Tuesday as it traded at $4.74 compared with its previous 52-Week low of $4.81. PDL BioPharma is changing hands at $4.74 with 2.5 million shares traded as of 1:17 p.m. ET. Average volume has been 2.4 million shares over the past 30 days.

PDL BioPharma has a market cap of $687.9 million and is part of the health care sector and drugs industry. Shares are down 20.9% year to date as of the close of trading on Friday.

PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. Its Queen et al. The company has a P/E ratio of 6.4, above the average drugs industry P/E ratio of 6.2 and below the S&P 500 P/E ratio of 23.2.

TheStreet Ratings rates PDL BioPharma as sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and generally disappointing historical performance in the stock itself. You can view the full PDL BioPharma Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

For more information on PDL BioPharma Inc. click any of the following:

• PDL BioPharma Inc. Stock Price

• PDL BioPharma Inc. Analyst Ratings

• PDL BioPharma Inc. Key Stats & Profile

• PDL BioPharma Inc. Earnings

• PDL BioPharma Inc. Ratio Comparison

• PDL BioPharma Inc. Growth Rates

• PDL BioPharma Inc. Balance Sheet

• PDL BioPharma Inc. Cash Flow

• PDL BioPharma Inc. Income Statement